EP2815766 - Compositions and methods for antibodies targeting complement protein C5 [Right-click to bookmark this link] | Status | No opposition filed within time limit Status updated on 11.05.2018 Database last updated on 11.12.2019 | |
Former | The patent has been granted Status updated on 02.06.2017 | ||
Former | Grant of patent is intended Status updated on 23.01.2017 | ||
Former | Examination is in progress Status updated on 16.11.2016 | Most recent event Tooltip | 22.11.2019 | Lapse of the patent in a contracting state New state(s): MK | published on 25.12.2019 [2019/52] | Applicant(s) | For all designated states Novartis AG Lichtstrasse 35 4056 Basel / CH | [2014/52] | Inventor(s) | 01 /
Diefenbach-Streiber, Beate Reiherweg 6 86949 Windach / DE | 02 /
Eberth, Adina Friedrich-List Strasse 114 81377 München / DE | 03 /
Guild, Braydon Charles 109 Riverdale Road Concord, MA 01742 / US | 04 /
Kim, Yong-In Novartis Institutes for Biomedical Research Inc. 500 Technology Square Cambridge, MA 02139 / US | 05 /
Roguska, Michael Novartis Institutes for BioMedical Research Inc. 500 Technology Square Cambridge, MA 02139 / US | 06 /
Splawski, Igor Novartis Institutes for BioMedical Research Inc. 500 Technology Square Cambridge, MA 02139 / US | [2014/52] | Representative(s) | Wood, Jonathan Paul Novartis Pharma AG Patent Department 4002 Basel / CH | [2014/52] | Application number, filing date | 14175571.0 | 03.08.2009 | [2014/52] | Priority number, date | US20080086355P | 05.08.2008 Original published format: US 86355 P | [2014/52] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | EP2815766 | Date: | 24.12.2014 | Language: | EN | [2014/52] | Type: | B1 Patent specification | No.: | EP2815766 | Date: | 05.07.2017 | Language: | EN | [2017/27] | Search report(s) | (Supplementary) European search report - dispatched on: | EP | 25.11.2014 | Classification | International: | A61K39/395, C07K16/18 | [2014/52] | Designated contracting states | AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR [2015/32] |
Former [2014/52] | AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR | Extension states | AL | 24.06.2015 | BA | 24.06.2015 | RS | 24.06.2015 | Title | German: | Zusammensetzungen und Verfahren für auf das Komplementprotein C5 gerichtete Antikörper | [2014/52] | English: | Compositions and methods for antibodies targeting complement protein C5 | [2014/52] | French: | Compositions et procédés pour des anticorps ciblant une protéine du complément C5 | [2014/52] | Examination procedure | 24.06.2015 | Amendment by applicant (claims and/or description) | 24.06.2015 | Examination requested [2015/32] | 04.01.2016 | Despatch of a communication from the examining division (Time limit: M04) | 02.05.2016 | Reply to a communication from the examining division | 02.06.2016 | Despatch of a communication from the examining division (Time limit: M02) | 27.07.2016 | Reply to a communication from the examining division | 15.09.2016 | Communication of intention to grant the patent | 11.11.2016 | Disapproval of the communication of intention to grant the patent by the applicant or resumption of examination proceedings by the EPO | 24.01.2017 | Communication of intention to grant the patent | 24.05.2017 | Fee for grant paid | 24.05.2017 | Fee for publishing/printing paid | 24.05.2017 | Receipt of the translation of the claim(s) | Parent application(s) Tooltip | EP09737379.9 / EP2328616 | Opposition(s) | 06.04.2018 | No opposition filed within time limit [2018/24] | Fees paid | Renewal fee | 03.11.2014 | Renewal fee patent year 03 | 03.11.2014 | Renewal fee patent year 04 | 03.11.2014 | Renewal fee patent year 05 | 14.10.2014 | Renewal fee patent year 06 | 10.08.2015 | Renewal fee patent year 07 | 11.08.2016 | Renewal fee patent year 08 | Lapses during opposition Tooltip | HU | 03.08.2009 | AT | 05.07.2017 | CY | 05.07.2017 | CZ | 05.07.2017 | DK | 05.07.2017 | EE | 05.07.2017 | FI | 05.07.2017 | HR | 05.07.2017 | LT | 05.07.2017 | LV | 05.07.2017 | MC | 05.07.2017 | MK | 05.07.2017 | NL | 05.07.2017 | PL | 05.07.2017 | RO | 05.07.2017 | SE | 05.07.2017 | SI | 05.07.2017 | SK | 05.07.2017 | SM | 05.07.2017 | IE | 03.08.2017 | IT | 03.08.2017 | LU | 03.08.2017 | MT | 03.08.2017 | BE | 31.08.2017 | CH | 31.08.2017 | LI | 31.08.2017 | BG | 05.10.2017 | NO | 05.10.2017 | GR | 06.10.2017 | IS | 05.11.2017 | [2019/52] |
Former [2019/47] | HU | 03.08.2009 | |
AT | 05.07.2017 | ||
CY | 05.07.2017 | ||
CZ | 05.07.2017 | ||
DK | 05.07.2017 | ||
EE | 05.07.2017 | ||
FI | 05.07.2017 | ||
HR | 05.07.2017 | ||
LT | 05.07.2017 | ||
LV | 05.07.2017 | ||
MC | 05.07.2017 | ||
NL | 05.07.2017 | ||
PL | 05.07.2017 | ||
RO | 05.07.2017 | ||
SE | 05.07.2017 | ||
SI | 05.07.2017 | ||
SK | 05.07.2017 | ||
SM | 05.07.2017 | ||
IE | 03.08.2017 | ||
IT | 03.08.2017 | ||
LU | 03.08.2017 | ||
MT | 03.08.2017 | ||
BE | 31.08.2017 | ||
CH | 31.08.2017 | ||
LI | 31.08.2017 | ||
BG | 05.10.2017 | ||
NO | 05.10.2017 | ||
GR | 06.10.2017 | ||
IS | 05.11.2017 | ||
Former [2019/31] | HU | 03.08.2009 | |
AT | 05.07.2017 | ||
CZ | 05.07.2017 | ||
DK | 05.07.2017 | ||
EE | 05.07.2017 | ||
FI | 05.07.2017 | ||
HR | 05.07.2017 | ||
LT | 05.07.2017 | ||
LV | 05.07.2017 | ||
MC | 05.07.2017 | ||
NL | 05.07.2017 | ||
PL | 05.07.2017 | ||
RO | 05.07.2017 | ||
SE | 05.07.2017 | ||
SI | 05.07.2017 | ||
SK | 05.07.2017 | ||
SM | 05.07.2017 | ||
IE | 03.08.2017 | ||
IT | 03.08.2017 | ||
LU | 03.08.2017 | ||
MT | 03.08.2017 | ||
BE | 31.08.2017 | ||
CH | 31.08.2017 | ||
LI | 31.08.2017 | ||
BG | 05.10.2017 | ||
NO | 05.10.2017 | ||
GR | 06.10.2017 | ||
IS | 05.11.2017 | ||
Former [2018/43] | AT | 05.07.2017 | |
CZ | 05.07.2017 | ||
DK | 05.07.2017 | ||
EE | 05.07.2017 | ||
FI | 05.07.2017 | ||
HR | 05.07.2017 | ||
LT | 05.07.2017 | ||
LV | 05.07.2017 | ||
MC | 05.07.2017 | ||
NL | 05.07.2017 | ||
PL | 05.07.2017 | ||
RO | 05.07.2017 | ||
SE | 05.07.2017 | ||
SI | 05.07.2017 | ||
SK | 05.07.2017 | ||
SM | 05.07.2017 | ||
IE | 03.08.2017 | ||
IT | 03.08.2017 | ||
LU | 03.08.2017 | ||
MT | 03.08.2017 | ||
BE | 31.08.2017 | ||
CH | 31.08.2017 | ||
LI | 31.08.2017 | ||
BG | 05.10.2017 | ||
NO | 05.10.2017 | ||
GR | 06.10.2017 | ||
IS | 05.11.2017 | ||
Former [2018/39] | AT | 05.07.2017 | |
CZ | 05.07.2017 | ||
DK | 05.07.2017 | ||
EE | 05.07.2017 | ||
FI | 05.07.2017 | ||
HR | 05.07.2017 | ||
LT | 05.07.2017 | ||
LV | 05.07.2017 | ||
MC | 05.07.2017 | ||
NL | 05.07.2017 | ||
PL | 05.07.2017 | ||
RO | 05.07.2017 | ||
SE | 05.07.2017 | ||
SI | 05.07.2017 | ||
SK | 05.07.2017 | ||
SM | 05.07.2017 | ||
IE | 03.08.2017 | ||
IT | 03.08.2017 | ||
LU | 03.08.2017 | ||
BE | 31.08.2017 | ||
CH | 31.08.2017 | ||
LI | 31.08.2017 | ||
BG | 05.10.2017 | ||
NO | 05.10.2017 | ||
GR | 06.10.2017 | ||
IS | 05.11.2017 | ||
Former [2018/34] | AT | 05.07.2017 | |
CZ | 05.07.2017 | ||
DK | 05.07.2017 | ||
EE | 05.07.2017 | ||
FI | 05.07.2017 | ||
HR | 05.07.2017 | ||
LT | 05.07.2017 | ||
LV | 05.07.2017 | ||
MC | 05.07.2017 | ||
NL | 05.07.2017 | ||
PL | 05.07.2017 | ||
RO | 05.07.2017 | ||
SE | 05.07.2017 | ||
SK | 05.07.2017 | ||
SM | 05.07.2017 | ||
IE | 03.08.2017 | ||
LU | 03.08.2017 | ||
CH | 31.08.2017 | ||
LI | 31.08.2017 | ||
BG | 05.10.2017 | ||
NO | 05.10.2017 | ||
GR | 06.10.2017 | ||
IS | 05.11.2017 | ||
Former [2018/24] | AT | 05.07.2017 | |
CZ | 05.07.2017 | ||
DK | 05.07.2017 | ||
EE | 05.07.2017 | ||
FI | 05.07.2017 | ||
HR | 05.07.2017 | ||
LT | 05.07.2017 | ||
LV | 05.07.2017 | ||
MC | 05.07.2017 | ||
NL | 05.07.2017 | ||
PL | 05.07.2017 | ||
RO | 05.07.2017 | ||
SE | 05.07.2017 | ||
SK | 05.07.2017 | ||
SM | 05.07.2017 | ||
CH | 31.08.2017 | ||
LI | 31.08.2017 | ||
BG | 05.10.2017 | ||
NO | 05.10.2017 | ||
GR | 06.10.2017 | ||
IS | 05.11.2017 | ||
Former [2018/23] | AT | 05.07.2017 | |
CZ | 05.07.2017 | ||
DK | 05.07.2017 | ||
EE | 05.07.2017 | ||
FI | 05.07.2017 | ||
HR | 05.07.2017 | ||
LT | 05.07.2017 | ||
LV | 05.07.2017 | ||
MC | 05.07.2017 | ||
NL | 05.07.2017 | ||
PL | 05.07.2017 | ||
RO | 05.07.2017 | ||
SE | 05.07.2017 | ||
SK | 05.07.2017 | ||
CH | 31.08.2017 | ||
LI | 31.08.2017 | ||
BG | 05.10.2017 | ||
NO | 05.10.2017 | ||
GR | 06.10.2017 | ||
IS | 05.11.2017 | ||
Former [2018/21] | AT | 05.07.2017 | |
CZ | 05.07.2017 | ||
DK | 05.07.2017 | ||
FI | 05.07.2017 | ||
HR | 05.07.2017 | ||
LT | 05.07.2017 | ||
LV | 05.07.2017 | ||
NL | 05.07.2017 | ||
PL | 05.07.2017 | ||
SE | 05.07.2017 | ||
CH | 31.08.2017 | ||
LI | 31.08.2017 | ||
BG | 05.10.2017 | ||
NO | 05.10.2017 | ||
GR | 06.10.2017 | ||
IS | 05.11.2017 | ||
Former [2018/12] | AT | 05.07.2017 | |
FI | 05.07.2017 | ||
HR | 05.07.2017 | ||
LT | 05.07.2017 | ||
LV | 05.07.2017 | ||
NL | 05.07.2017 | ||
PL | 05.07.2017 | ||
SE | 05.07.2017 | ||
BG | 05.10.2017 | ||
NO | 05.10.2017 | ||
GR | 06.10.2017 | ||
IS | 05.11.2017 | ||
Former [2018/11] | AT | 05.07.2017 | |
FI | 05.07.2017 | ||
HR | 05.07.2017 | ||
LT | 05.07.2017 | ||
NL | 05.07.2017 | ||
PL | 05.07.2017 | ||
SE | 05.07.2017 | ||
BG | 05.10.2017 | ||
NO | 05.10.2017 | ||
GR | 06.10.2017 | ||
IS | 05.11.2017 | ||
Former [2018/10] | AT | 05.07.2017 | |
FI | 05.07.2017 | ||
HR | 05.07.2017 | ||
LT | 05.07.2017 | ||
NL | 05.07.2017 | ||
SE | 05.07.2017 | ||
NO | 05.10.2017 | ||
Former [2018/09] | FI | 05.07.2017 | |
LT | 05.07.2017 | ||
NL | 05.07.2017 | ||
SE | 05.07.2017 | ||
NO | 05.10.2017 | ||
Former [2018/08] | FI | 05.07.2017 | |
LT | 05.07.2017 | ||
NL | 05.07.2017 | ||
NO | 05.10.2017 | ||
Former [2018/07] | LT | 05.07.2017 | |
NO | 05.10.2017 | Documents cited: | Search | [XY]US2006115476 (TEDESCO FRANCESCO [IT], et al) [X] 1-26,28 * examples 1-12 * [Y] 34,35; | [XY]WO9529697 (ALEXION PHARMA INC [US], et al) [X] 1-14,27,36-39 * examples 1-15 * [Y] 34,35; | [XY]WO0230985 (TANOX INC [US]) [X] 1-14 * figure 2 * * examples 1-3 * [Y] 34,35; | [Y]US2007196367 (DINU VALENTIN [US]) [Y] 34,35 * paragraphs [0061] - [0063] *; | [X]WO02086085 (BAYER AG [US], et al) [X] 29-33 * sequence 115 * * paragraphs [0082] , [0083] , [0120] * | [XY] - CICCHETTI F ET AL, "Immune parameters relevant to neural xenograft survival in the primate brain", XENOTRANSPLANTATION, MUNKSGAARD, DE, (20030101), vol. 10, no. 1, ISSN 0908-665X, pages 41 - 49, XP002410883 [X] 1-5 * page 42 * * table 1 * * pages 44-46 * * figures 1,2 * [Y] 34,35 DOI: http://dx.doi.org/10.1034/j.1399-3089.2003.01130.x | [IY] - ROTHER RUSSELL P ET AL, "Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria.", NATURE BIOTECHNOLOGY NOV 2007, (200711), vol. 25, no. 11, ISSN 1087-0156, pages 1256 - 1264, XP002553743 [I] 1-26,28 * the whole document * [Y] 34,35 DOI: http://dx.doi.org/10.1038/nbt1344 | [A] - HOLERS V MICHAEL, "The spectrum of complement alternative pathway-mediated diseases.", IMMUNOLOGICAL REVIEWS JUN 2008, (200806), vol. 223, ISSN 1600-065X, pages 300 - 316, XP002553744 [A] 1-39 * the whole document * DOI: http://dx.doi.org/10.1111/j.1600-065X.2008.00641.x | by applicant | US6703199 | US5641870 | US5766886 | US5225539 | US5530101 | US5585089 | US5693762 | US6180370 | US6818418 | US2004175756 | US2005053973 | US2005048512 | US2006008844 | US5831012 | WO9916873 | WO0104144 | WO2004106368 | US2005008625 | US2003198971 | US2003157579 | WO9404678 | US5759808 | US2004161738 | US4946778 | US5260203 | US5455030 | US4881175 | US5132405 | US5091513 | US5476786 | US5013653 | US5258498 | US5482858 | EP1012280 | EP0154316 | EP0401384 | WO9823289 | WO9734631 | US6277375 | WO9315199 | WO9315200 | WO0177137 | EP0413622 | US5336603 | US5622929 | US5359046 | US5349053 | US5447851 | US5112946 | EP0307434 | EP0367166 | WO9604388 | WO9106570 | US5605793 | US5811238 | US5830721 | US5834252 | US5837458 | US4458066 | US4816567 | US5545806 | US5569825 | US5625126 | US5633425 | US5789650 | US5877397 | US5661016 | US5814318 | US5874299 | US5770429 | US5545807 | WO9203918 | WO9312227 | WO9425585 | WO9713852 | WO9824884 | WO9945962 | WO0114424 | WO0243478 | US5939598 | US6075181 | US6114598 | US6150584 | US6162963 | US5223409 | US5403484 | US5571698 | US5427908 | US5580717 | US5969108 | US6172197 | US5885793 | US6521404 | US6544731 | US6555313 | US6582915 | US6593081 | US5476996 | US5698767 | US2003153043 | US5677425 | US6165745 | US5869046 | US6121022 | US5624821 | US5648260 | US6194551 | WO9429351 | WO0042072 | US5714350 | US6350861 | EP1176195 | WO03035835 | WO9954342 | US2005255552 | WO02092780 | WO03074679 | US6087120 | US5843449 | US6218368 | US5808109 | US2006067935 | WO0105950 | US6355245 | - MARZARI ET AL., EUR J IMMUNOL, (2002), vol. 32, pages 2773 - 2782 | - TRENDELENBURG, SWISS MED WKLY, (2007), vol. 137, pages 413 - 417 | - WARD ET AL., NATURE, (1989), vol. 341, pages 544 - 546 | - BIRD ET AL., SCIENCE, (1988), vol. 242, pages 423 - 426 | - HUSTON ET AL., PROC. NATL. ACAD. SCI., (1988), vol. 85, pages 5879 - 5883 | - HOLLINGER; HUDSON, NATURE BIOTECHNOLOGY, (2005), vol. 23, no. 9, pages 1126 - 1136 | - ZAPATA ET AL., PROTEIN ENG., (1995), vol. 8, no. 10, pages 1057 - 1062 | - MORRISON ET AL., PROC. NATL. ACAD. SCI. USA, (1984), vol. 81, pages 6851 - 6855 | - MORRISON; OI, ADV. IMMUNOL., (1988), vol. 44, pages 65 - 92 | - VERHOEYEN ET AL., SCIENCE, (1988), vol. 239, pages 1534 - 1536 | - PADLAN, MOLEC. IMMUN., (1991), vol. 28, pages 489 - 498 | - PADLAN, MOLEC. IMMUN., (1994), vol. 31, pages 169 - 217 | - SMITH; WATERMAN, ADV. APPL. MATH., (1970), vol. 2, page 482C | - NEEDLEMAN; WUNSCH, J. MOL. BIOL., (1970), vol. 48, page 443 | - PEARSON; LIPMAN, PROC. NAT'L. ACAD. SCI. USA, (1988), vol. 85, page 2444 | - GAP, BESTFIT, FASTA, AND TFASTA IN THE WISCONSIN GENETICS SOFTWARE PACKAGE | - ALTSCHUL ET AL., NUC. ACIDS RES., (1977), vol. 25, pages 3389 - 3402 | - ALTSCHUL ET AL., J. MOL. BIOL., (1990), vol. 215, pages 403 - 410 | - HENIKOFF; HENIKOFF, PROC. NATL. ACAD. SCI. USA, (1989), vol. 89, page 10915 | - KARLIN; ALTSCHUL, PROC. NATL. ACAD. SCI. USA, (1993), vol. 90, pages 5873 - 5787 | - E. MEYERS; W. MILLER, COMPUT. APPL. BIOSCI., (1988), vol. 4, pages 11 - 17 | - NEEDLEMAN; WUNSCH, J. MOL, BIOL., (1970), vol. 48, pages 444 - 453 | - BATZER ET AL., NUCLEIC ACID RES., (1991), vol. 19, page 5081 | - OHTSUKA E, J. BIOL. CHEM., (1985), vol. 260, pages 2605 - 2608 | - ROSSOLINI ET AL., MOL. CELL. PROBES, (1994), vol. 8, pages 91 - 98 | - ALTSCHUL ET AL., J.MOL. BIOL., (1990), vol. 215, pages 403 - 10 | - RIECHMANN, L. ET AL., NATURE, (1998), vol. 332, pages 323 - 327 | - JONES, P. ET AL., NATURE, (1986), vol. 321, pages 522 - 525 | - QUEEN, C. ET AL., PROC. NATL. ACAD., U.S.A., (1989), vol. 86, pages 10029 - 10033 | - TOMLINSON, I. M. ET AL., J. FOL. BIOL., (1992), vol. 227, pages 776 - 798 | - COX, J. P. L. ET AL., EUR. J IMMUNOL., (1994), vol. 24, pages 827 - 836 | - STIJLEMANS, B. ET AL., J BIOL CHEM, (2004), vol. 279, pages 1256 - 1261 | - DUMOULIN, M. ET AL., NATURE, (2003), vol. 424, pages 783 - 788 | - PLESCHBERGER, M. ET AL., BIOCONJUGATE CHEM, (2003), vol. 14, pages 440 - 448 | - CORTEZ-RETAMOZO, V. ET AL., INT J CANCER, (2002), vol. 89, pages 456 - 62 | - LAUWEREYS, M. ET AL., EMBO J, (1998), vol. 17, pages 3512 - 3520 | - HOLLIGER ET AL., PROC. NATL. ACAD. SCI. USA, (1993), vol. 90, pages 6444 - 6448 | - POLJA ET AL., STRUCTURE, (1994), vol. 2, pages 1121 - 1123 | - HOLLIGER; WINTER, CANCER IMMUNOL. IMMUNOTHER., (1997), vol. 45, no. 3-4, pages 128 - 30 | - WU ET AL., IMMUNOTECHNOLOGY, (1996), vol. 2, no. 1, pages 21 - 36 | - HOLLIGER; WINTER, CANCER IMMUNOL. IMMUNOTHER., (1997), vol. 45, no. 34, pages 128 - 30 | - PLUCKTHUN; PACK, IMMUNOTECHNOLOGY, (1997), vol. 3, no. 2, pages 83 - 105 | - RIDGWAY ET AL., PROTEIN ENG., (1996), vol. 9, no. 7, pages 617 - 21 | - LU ET AL., J. BIOL. CHEM., (2004), vol. 279, no. 4, pages 2856 - 65 | - KARPOVSKY ET AL., J. EXP. MED., (1984), vol. 160, page 1686 | - LIU, MA ET AL., PROC. NATL. ACAD. SCI. USA, (1985), vol. 82, page 8648 | - PAULUS, BEHRING INS. MITT. NO. 78, (1985), pages 118 - 132 | - BRENNAN ET AL., SCIENCE, (1985), vol. 229, pages 81 - 83 | - GLENNIE ET AL., J. IMMUNOL., (1987), vol. 139, pages 2367 - 2375 | - ASHKENAZI ET AL., PROC. NATL. ACAD. SCI. USA, (1991), vol. 88, pages 10535 - 10539 | - ZHENG ET AL., J. IMMUNOL., (1995), vol. 154, pages 5590 - 5600 | - VIL ET AL., PROC. NATL. ACAD. SCI. USA, (1992), vol. 89, pages 11337 - 11341 | - PATTEN ET AL., CURR. OPINION BIOTECHNOL., (1997), vol. 8, pages 724 - 33 | - HARAYAMA, TRENDS BIOTECHNOL., (1998), vol. 16, no. 2, pages 76 - 82 | - HANSSON ET AL., J. MOL. BIOL., (1999), vol. 287, pages 265 - 76 | - LORENZO; BLASCO, BIOTECHNIQUES, (1998), vol. 24, no. 2, pages 308 - 313 | - GENTZ ET AL., PROC. NATL. ACAD. SCI. USA, (1989), vol. 86, pages 821 - 824 | - WILSON ET AL., CELL, (1984), vol. 37, page 767 | - DENARDO ET AL., CLIN CANCER RES., (1998), vol. 4, no. 10, pages 2483 - 90 | - PETERSON ET AL., BIOCONJUG. CHEM., (1999), vol. 10, no. 4, pages 553 - 7 | - ZIMMERMAN ET AL., NUCL. MED. BIOL., (1999), vol. 26, no. 8, pages 943 - 50 | - ARNON ET AL., "Monoclonal Antibodies For Immunotargeting Of Drugs In Cancer Therapy", ARNON ET AL., REISFELD ET AL., Monoclonal Antibodies And Cancer Therapy, ALAN R. LISS, INC., (1985), pages 243 - 56 | - HELLSTROM ET AL., "Antibodies For Drug Delivery", HELLSTROM ET AL., ROBINSON ET AL., Controlled Drug Delivery, 2nd ed., MARCEL DEKKER, INC., (1987), pages 623 - 53 | - THORPE ET AL., "Antibody Carriers Of Cytotoxic Agents In Cancer Therapy: A Review", THORPE ET AL., PINCHERA ET AL., Monoclonal Antibodies 84: Biological And Clinical Applications, (1985), pages 475 - 506 | - "Analysis, Results, And Future Prospective Of The Therapeutic Use Of Radiolabeled Antibody In Cancer Therapy", BALDWIN ET AL., Monoclonal Antibodies For Cancer Detection And Therapy, ACADEMIC PRESS, (1985), pages 303 - 16 | - THORPE ET AL., IMMUNOL. REV., (1982), vol. 62, pages 119 - 58 | - NARANG ET AL., METH. ENZYMOL., (1979), vol. 68, page 90 | - BROWN ET AL., METH. ENZYMOL., (1979), vol. 68, page 109 | - BEAUCAGE ET AL., TETRA. LETT., (1981), vol. 22, page 1859 | - MATTILA ET AL., NUCLEIC ACIDS RES., (1991), vol. 19, page 967 | - ECKERT ET AL., PCR METHODS AND APPLICATIONS, (1991), vol. 1, page 17 | - HARRINGTON ET AL., NAT GENET, (1997), vol. 15, page 345 | - SMITH, ANNU. REV. MICROBIOL., (1995), vol. 49, page 807 | - ROSENFELD ET AL., CELL, (1992), vol. 68, page 143 | - SCHARF ET AL., RESULTS PROBL. CELL DIFFER., (1994), vol. 20, page 125 | - BITTNER ET AL., METH. ENZYMOL., (1987), vol. 153, page 516 | - QUEEN ET AL., IMMUNOL. REV., (1986), vol. 89, pages 49 - 68 | - ELLIOT; O'HARE, CELL, (1997), vol. 88, page 223 | - KOHLER; MILSTEIN, NATURE, (1975), vol. 256, page 495 | - LONBERG ET AL., NATURE, (1994), vol. 368, no. 6474, pages 856 - 859 | - LONBERG, N, Handbook of Experimental Pharmacology, (1994), vol. 113, pages 49 - 101 | - LONBERG, N; HUSZAR, D., INTERN. REV. IMMUNOL., (1995), vol. 13, pages 65 - 93 | - HARDING, F.; LONBERG, N., ANN. N. Y. ACAD. SCI., (1995), vol. 764, pages 536 - 546 | - TAYLOR, L. ET AL., NUCLEIC ACIDS RESEARCH, (1992), vol. 20, pages 6287 - 6295 | - CHEN, J., INTERNATIONAL IMMUNOLOGY, (1993), vol. 5, pages 647 - 656 | - TUAILLON ET AL., PROC. NATL. ACAD. SCI. USA, (1993), vol. 94, pages 3720 - 3724 | - CHOI ET AL., NATURE GENETICS, (1993), vol. 4, pages 117 - 123 | - CHEN, J. ET AL., EMBO J., (1993), vol. 12, pages 821 - 830 | - TUAILLON ET AL., J. IMMUNOL., (1994), vol. 152, pages 2912 - 2920 | - TAYLOR, L. ET AL., INTERNATIONAL IMMUNOLOGY, (1994), pages 579 - 591 | - FISHWILD, D. ET AL., NATURE BIOTECHNOLOGY, (1996), vol. 14, pages 845 - 851 | - TOMIZUKA ET AL., PROC. NATL. ACAD. SCI. USA, (2000), vol. 97, pages 722 - 727 | - KUROIWA ET AL., NATURE BIOTECHNOLOGY, (2002), vol. 20, pages 889 - 894 | - SHIELDS, R.L. ET AL., J. BIOL. CHEN., (2001), vol. 276, pages 6591 - 6604 | - SHIELDS, R.L. ET AL., J. BIOL. CHEM., (2002), vol. 277, pages 26733 - 26740 | - UMANA ET AL., NAT. BIOTECH., (1999), vol. 17, pages 176 - 180 | - NEWELL ET AL., J LAB CLIN MED, (1982), vol. 100, pages 437 - 44 | - BAATRUP ET AL., ANN RHEUM DIS, (1992), vol. 51, pages 892 - 7 | - AUD ET AL., RHEUMATOL INT, (1990), vol. 10, pages 185 - 9 | - CHAIN ET AL., J IMMUNOL METHODS, (1987), vol. 99, pages 221 - 8 | - FORSTROM ET AL., NATURE, (1983), vol. 303, pages 627 - 629 | - HALLIDAY ET AL., Assessment of Immune Status by the Leukocyte Adherence Inhibition Test, ACADEMIC, (1982), pages 1 - 26 | - KOPPI ET AL., CELL. IMMUNOL., (1982), vol. 66, pages 394 - 406 | - DIJK ET AL., J IMMUNOL METHODS, (1980), vol. 36, pages 29 - 39 | - MINH ET AL., CLIN LAB HAEMATOL., (1983), vol. 5, pages 23 - 34 | - TANAKA ET AL., J IMMUNOL, (1986), vol. 86, pages 161 - 170 | - STAHLI ET AL., METHODS IN ENZYMOLOGY, (1983), vol. 9, pages 242 - 253 | - KIRKLAND ET AL., J. IMMUNOL., (1986), vol. 137, pages 3614 - 3619 | - MOREL ET AL., MOLEC. IMMUNOL., (1988), vol. 25, pages 7 - 15 | - CHEUNG ET AL., VIROLOGY, (1990), vol. 176, pages 546 - 552 | - MOLDENHAUER ET AL., SCAND. J. IMMUNOL., (1990), vol. 32, pages 77 - 82 | - TAKADA ET AL., IMMUNOLOGY, (1978), vol. 34, page 509 | - BECKER, L., BIOCHEM. BIOPHY. ACTA, (1967), vol. 147, page 289 | - CONROW, R. B. ET AL., J. MED. CHEM., (1980), vol. 23, page 242 | - HANSCH, C.; YOSHIMOTO, M., J. MED. CHEM., (1974), vol. 17, page 1160 | - DECLERCQ, P. F. ET AL., BIOCHEM. BIOPHYS. RES. COMMUN, (1975), vol. 67, page 255 | - GLOVSKY, M. ET AL., J. IMMUNOL., (1969), vol. 102, page 1 | - LAPIDUS, M.; TOMASCO, J. IMMUNOPHARMACOL., (1981), vol. 3, page 137 | - BURGE, J. J ET AL., J. IMMUNOL., (1978), vol. 120, page 1625 | - MULLER-EBERHARD, H. J. ET AL., MULLER-EBERHARD, H. J. ET AL., BERLIN, R. D. ET AL., Molecular Basis of Biological Degradative Processes, ACADEMIC PRESS, (1978), page 65 | - VOGT, W. ET AL., IMMUNOLOGY, (1979), vol. 36, page 138 | - VOGT ET AL., IMMUNOL., (1979), vol. 36, page 138 | - COREY ET AL., J. AMER. CHEM. SOC., (1982), vol. 104, page 5551 | - HONG ET AL., J. IMMUNOL., (1979), vol. 122, page 2418 | - MIYAZAKI ET AL., MICROBIOL. IMMUNOL., (1980), vol. 24, page 1091 | - BUMPERS ET AL., LAB. CLINC. MED., (1983), vol. 102, page 421 | - HONG ET AL., J. IMMUNOL., (1981), vol. 127, pages 104 - 108 | - WEINBERG, WEINBERG, FOYE, W. O., Principles of Medicinal Chemistry, 2nd ed., LEA & FEBIGER, (1981), page 813 | - DJURA ET AL., AUST. J. CHEM., (1983), vol. 36, page 1057 | - SULLIVAN ET AL., TETRAHEDRON, (1981), vol. 37, page 979 | - HUGLI ET AL., IMMUNOASSAYS CLINICAL LABORATORY TECHNIQUES, (1980), pages 443 - 460 | - GORSKI ET AL., J IMMUNOL METH, (1981), vol. 47, pages 61 - 73 | - LINDER ET AL., J IMMUNOL METH, (1981), vol. 47, pages 49 - 59 | - BURGER ET AL., J IMMUNOL, (1988), vol. 141, pages 553 - 558 | - CHENOWETH ET AL., N ENGL J MED, (1981), vol. 304, pages 497 - 502 | - BHAKDI ET AL., BIOCHIM BIOPHYS ACTA, (1983), vol. 737, pages 343 - 372 | - CHEN ET AL., GENE, (1994), vol. 139, pages 73 - 75 | - KREBS ET AL., J. IMMUNOL. METHODS, (2001), vol. 254, pages 67 - 84 | - VIRNEKAS ET AL., NUCLEIC ACIDS RES., (1994), vol. 22, pages 5600 - 5607 | - RAUCHENBERGER ET AL., J. BIOL. CHEM., (2003), vol. 278, pages 38194 - 38205 | - CHEN ET AL., J. MOL. BIOL., (1999), vol. 293, pages 865 - 881 | - SCHIER ET AL., J. MOL. BIOL., (1996), vol. 263, pages 551 - 567 | - FRIGUET ET AL., J. IMMUNOL METHODS, (1985), vol. 77, pages 305 - 319 | - HAENEL ET AL., ANAL BIOCHEM, (2005), vol. 339, pages 182 - 184 | - EVANS ET AL., MOL. IMMUNOL, (1995), vol. 32, pages 1183 - 1195 | - THOMAS ET AL., MOL IMMUNOL, (1996), vol. 33, pages 1389 - 1401 | - RINDER ET AL., J CLIN INVEST, (1995), vol. 96, pages 1564 - 1572 | WO1997EP05897 |